- Home
- ALLT vs PLYX Comparison
ALLT vs PLYX Comparison
Compare ALLT & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLT | PLYX |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.6M | 114.1M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALLT | PLYX |
|---|---|---|
| Price | $6.40 | $6.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $12.25 | $10.00 |
| AVG Volume (30 Days) | 691.6K | ★ 3.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.86 | N/A |
| Revenue Next Year | $12.10 | N/A |
| P/E Ratio | $469.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.37 | $2.20 |
| 52 Week High | $11.92 | $8.15 |
Technical Indicators
Market Signals| Indicator | ALLT | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 27.56 | 58.11 |
| Support Level | $6.20 | $2.44 |
| Resistance Level | $8.20 | $7.39 |
| Average True Range (ATR) | 0.55 | 0.90 |
| MACD | -0.06 | 0.46 |
| Stochastic Oscillator | 6.30 | 79.72 |
Price Performance
Historical ComparisonAbout ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About PLYX Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.